100 related articles for article (PubMed ID: 15337488)
1. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin.
Jones RL; Berry GJ; Rubens RD; Miles DW
Lancet Oncol; 2004 Sep; 5(9):575-7. PubMed ID: 15337488
[No Abstract] [Full Text] [Related]
2. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
3. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
Byrnes KW; DeBenedetti A; Holm NT; Luke J; Nunez J; Chu QD; Meschonat C; Abreo F; Johnson LW; Li BD
J Am Coll Surg; 2007 May; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Minisini AM; Andreetta C; Fasola G; Puglisi F
Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
7. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
9. Potential cardiotoxicity with the use of DuP-941: a case report.
Walsh SM; Walley VM; Chandra L; Huan SD; Veinot JP; Higginson LA
Can J Cardiol; 1995 May; 11(5):419-22. PubMed ID: 7750038
[TBL] [Abstract][Full Text] [Related]
10. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
11. [Improving prognosis with docetaxel and monoclonal antibodies].
Krankenpfl J; 2005; 43(7-10):233. PubMed ID: 16515303
[No Abstract] [Full Text] [Related]
12. Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review.
Hsieh CL; Chang TC; Lai CH; Jung SM; Chou HH
Gynecol Oncol; 2004 Sep; 94(3):854-7. PubMed ID: 15350389
[TBL] [Abstract][Full Text] [Related]
13. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
Bernardi D; Errante D; Stefani M; Salvagno L
Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
[No Abstract] [Full Text] [Related]
14. Cardiotoxicity after liposomal anthracyclines.
Young AM; Dhillon T; Bower M
Lancet Oncol; 2004 Nov; 5(11):654. PubMed ID: 15522651
[No Abstract] [Full Text] [Related]
15. [Radiotherapy of breast carcinoma. 2005 version].
Organgruppe "Mammakarzinom" der DEGRO
Strahlenther Onkol; 2006 Feb; 182 Suppl 1():4-28. PubMed ID: 16613299
[No Abstract] [Full Text] [Related]
16. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Blum RH
Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
[No Abstract] [Full Text] [Related]
17. [Caelyx once again recommended in recurrent ovarian carcinoma].
Krankenpfl J; 2005; 43(7-10):232. PubMed ID: 16518888
[No Abstract] [Full Text] [Related]
18. [Medical treatment of malignant bone tumors (carcinolytics, hormonotherapy, immunotherapy)].
Clavel B
Sem Hop; 1974 Jan; 50(4):287-95. PubMed ID: 4368180
[No Abstract] [Full Text] [Related]
19. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
[Next] [New Search]